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Rett syndrome (RTT) is caused by mutations of
MECP2, a methyl CpG binding protein thought to act
as a global transcriptional repressor. Here we show,
using an isogenic human embryonic stem cell model
of RTT, that MECP2 mutant neurons display key
molecular and cellular features of this disorder. Unbi-
ased global gene expression analyses demonstrate
that MECP2 functions as a global activator in
neurons but not in neural precursors. Decreased tran-
scription in neurons was coupled with a significant
reduction in nascent protein synthesis and lack of
MECP2 was manifested as a severe defect in the
activity of the AKT/mTOR pathway. Lack of MECP2
also leads to impaired mitochondrial function in
mutant neurons. Activation of AKT/mTOR signaling
by exogenous growth factors or by depletion of
PTEN boosted protein synthesis and ameliorated
disease phenotypes in mutant neurons. Our findings
indicate a vital function for MECP2 in maintaining
active gene transcription in human neuronal cells.
INTRODUCTION
Rett syndrome (RTT) is a monogenic X-linked neurodevelop-
mental disease that belongs to autism spectrum disorders
(ASDs). It has been well established that mutations in the
MECP2 gene account for the majority of RTT cases (Amir
et al., 1999). We and others have generatedmutant mice bearing
loss-of-function alleles of Mecp2 and showed that they recapit-
ulate many of the cellular and behavioral phenotypes of RTT
patients (Chen et al., 2001; Guy et al., 2001). Recent work using
thesemousemodels demonstrated that the disease pathology in
Mecp2 mutant mice could be reversed either via re-expression
of the wild-type Mecp2 gene (Giacometti et al., 2007; Guy446 Cell Stem Cell 13, 446–458, October 3, 2013 ª2013 Elsevier Inc.et al., 2007) or by exogenous growth factors (Chang et al.,
2006; Tropea et al., 2009). These findings serve as important
proof-of-principle evidence that RTT, and perhaps ASD in gen-
eral, are treatable disorders. With the advent of induced pluripo-
tent stem cell (iPSC) technology (Takahashi et al., 2007; Yu et al.,
2007), it has become feasible to confirm conclusions from animal
models in human cells by deriving patient-specific iPSCs for dis-
ease modeling and therapeutic investigation (Ananiev et al.,
2011; Cheung et al., 2011; Marchetto et al., 2010). However,
due to differences in genetic background and method of deriva-
tion, human embryonic stem cells (ESCs) and iPSCs display
highly variable biological characteristics such as propensity to
differentiate into specific lineages, complicating their use in dis-
ease modeling (Soldner and Jaenisch, 2012). This is of particular
relevance to RTT, in which genetic background has been
demonstrated to influence the severity of disease symptoms
(Scala et al., 2007). To overcome this complication, isogenic
experimental and control cells that differ exclusively at the dis-
ease-causing genetic alteration have been generated, allowing
the study of disease-specific phenotypes under highly controlled
conditions (Soldner et al., 2011).
It has been well established that MECP2 protein is abundantly
present in neuronal cell types and binds methylated CpG sites
throughout the neuronal genome (Skene et al., 2010). Such bind-
ing specificity and mode of distribution strongly suggested that
MECP2 functions as a global transcriptional repressor (Nan
et al., 1997). However, the role ofMECP2 as a repressor received
little support from in vivo studies because exhaustive gene
expression analyses on presymptomatic and postsymptomatic
mutant mice provided little evidence of global transcriptional
activation (Ben-Shachar et al., 2009; Chahrour et al., 2008; Jor-
dan et al., 2007; Kriaucionis et al., 2006; Nuber et al., 2005; Tudor
et al., 2002; Urdinguio et al., 2008).
In the present study, we used TALEN-mediated gene editing
to generate human ESCs with a loss-of-function MECP2 allele.
This strategy ensures that neuronal cells derived from the control
and mutant ESCs differ only at the MECP2 gene. We found that
although neural precursors (NPs) derived from mutant ESCs
were largely normal as compared to their isogenic controls, an
Figure 1. Generation of Isogenic Pairs of Control and MECP2 Mutant Human ESCs, NPs, and Neurons
(A) Schematic overview depicting the targeting strategy for the MECP2 locus.
(B) Southern blot analysis of WIBR1 and WIBR3 ESCs targeted with the MECP2exon3-GFP-PGK-PURO donor construct, using probes against the 50 external
sequence, showing targeted bands at 6.7 kb, and wild-type band at 3.6 kb.
(C) Immunostaining for markers of ESC (Nanog), NPs (Pax6 and Nestin), and neurons (Tuj1 and MAP2) documents the stepwise differentiation process. Both
excitatory (vGlut1) and inhibitory (GAD67) neurons could be seen. Scale bar, 20 mm.
(D and E) MECP2 protein was specifically enriched in wild-type neurons compared to ESCs and NPs.
(F) Quantitative RT-PCR analysis confirmed the absence of MECP2 mRNA in WIBR1-Mut and WIBR3-Mut ESCs, NPs, and neurons.
(G) Immunoblot analyses for MECP2 confirmed complete ablation of wild-type MECP2 protein in WIBR1-Mut and WIBR3-Mut ESCs, NPs, and neurons.
(H) Quantification of neurons (MAP2+) and astrocytes (GFAP+) derived from control and MECP2 mutant NPs.
(I) Quantification of excitatory neurons (MAP2+vGlut1+) and inhibitory neurons (MAP2+GAD67+) derived from control and MECP2 mutant NPs.
Results are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.
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entiated MECP2 mutant neurons. To investigate the impact of
MECP2 deletion on the neuronal transcriptome, we adopted a
gene expression analysis method that took into consideration
possible global shifts in transcriptional activities. We found
a significant genome-wide transcriptional downregulation in
mutant neurons. This striking reduction of global transcription
was echoed in significantly decreased protein synthesis levels.
Pharmacological and genetic manipulations that boost protein
synthesis ameliorated RTT-related disease phenotypes. These
findings strongly support the notion that one of the key functions
of MECP2 is to facilitate global transcription.
RESULTS
TALEN-Mediated Targeting of the MECP2 Locus
To generate a MECP2 loss-of-function allele, we designed
TALENs to specifically target the third exon of the MECP2Cegene, which encodes most of the methyl-CpG-binding domain
(Figure 1A and Figure S1A available online). A donor construct
containing an in-frame eGFP-polyA sequence and a PGK-puro
cassette flanked by two homology arms corresponding to the
genomic sequence of the MECP2 gene was used for targeting
(Figure 1A). This targeting strategy disrupts gene function and
generates an endogenous reporter for MECP2 activity. We
used a male (WIBR1) and a female (WIBR3) ESC line to generate
MECP2 hemizygous mutant male and heterozygous mutant
female clones (Figures 1B, S1B, and S1C). The WIBR3 ESCs
were maintained in the XaXi state, in which the targeted
MECP2 allele resided on the active and the wild-type allele on
the inactive X chromosome. For subsequent analyses, we
used one pair of control and mutant WIBR1 ESCs (WIBR1-
Con, WIBR1-Mut) and two subclones each of the control and
mutant WIBR3 ESCs (WIBR3-Con1, WIBR3-Con2, WIBR3-
Mut1, WIBR3-Mut2). In addition, similar to their isogenic wild-
type controls, mutant ESCs maintained pluripotency markerll Stem Cell 13, 446–458, October 3, 2013 ª2013 Elsevier Inc. 447
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teratomas when injected subcutaneously into NOD/SCID mice
(Figures S1F and S1G).
Neural Differentiation of MECP2 Mutant ESCs
Human ESCs and iPSCs can generate NPs, which can be
induced to differentiate into different neural and glial subtypes
(Soldner et al., 2009). To generate a homogenous population of
NPs from control and MECP2 mutant ESCs, we utilized a
SMAD-inhibition-based neural differentiation protocol (Cham-
bers et al., 2009; Zhou et al., 2010). Adherent cultures of control
and mutant ESCs were differentiated side-by-side into neural
rosettes and further expanded as NPs in the presence of
bFGF. These isogenic pairs of NPswere then cultured inmedium
that promotes terminal neural differentiation andmaturation (Fig-
ure 1C). Using antibodies specific to antigens of these lineages,
we demonstrate the generation of NPs (Pax6+, Nestin+) and
neurons (TuJ1+, MAP2+) from pluripotent ESCs (Nanog+) (Fig-
ure 1C). Furthermore, using antibodies against vGlut1 and
GAD67, we found that both excitatory and inhibitory neurons
were present in the neuronal cultures (Figure 1C).
MECP2 is expressed in ESCs and NPs but significantly more
abundantly in neurons, as shown by immunoblotting (Figures
1D and 1E). To confirm that the targeting strategy disrupted
the MECP2 locus, we isolated mRNA from control and mutant
ESCs, NPs, and neurons. Quantitative RT-PCR revealed the
absence of MECP2 expression in WIBR1-Mut and WIBR3-Mut
cells (Figure 1F). Immunoblotting confirmed the absence of
MECP2 protein (Figure 1G). Furthermore, wild-type MECP2 pro-
tein was not detectable by immunostaining (Figure S1E and not
shown). The lack of wild-type MECP2 mRNA and protein was
consistent with the hemizygous status of WIBR1-Mut ESCs
and the one X active (XaXi) state of WIBR3-Mut ESCs demon-
strating loss of function in WIBR1-Mut and WIBR3-Mut cells.
Control and mutant NPs displayed similar morphology (Fig-
ure S1H) and expressed comparable levels of markers indicative
of the cortical lineage (Figure S1I). Upon withdrawal of bFGF,
both control and mutant NPs readily generated Doublecortin+
immature neurons (Figure S1J). During the course of neuronal
differentiation, predominantly excitatory neurons were gener-
ated (Figures 1H and 1I). Expression of genes characteristic for
different cortical layers such as Calretinin (subplate), Reelin
(layer I), FoxP2 (layer V/VI), CTIP2 (layer II to VI), and Cux2
(layer II) were similar in control and mutant cells (Figures S1K–
S1P). These finding suggest that MECP2 deletion did not alter
the differentiation potential of NPs.
MECP2 Mutant Neurons Show Morphological and
Physiological Defects
A prominent feature of RTT patients is microcephaly with the
reduction in brain size correlating with the reduction in neuronal
size (Akbarian, 2002; Chen et al., 2001). Consistent with these
findings, soma and nuclei of mutant neurons expressing MAP2
or marked by a Synapsin-GFP virus (Ku¨gler et al., 2003) dis-
played a significantly reduced size as compared to isogenic con-
trols (Figures 2A–2D). In contrast, mutant NPs displayed a similar
soma and nuclear size as compared to controls (not shown).
Because excitatory neurons comprise the majority of the mature
neurons generated in our differentiation protocol (Figure 1I), the448 Cell Stem Cell 13, 446–458, October 3, 2013 ª2013 Elsevier Inc.reduction of soma size mostly represents deficits in the
excitatory neuron population. Recent studies suggest that
cell-type-specific deletion of MeCP2 in inhibitory neurons was
sufficient to impair GABAergic function, leading to severe
behavior deficits (Chao et al., 2010). To investigate whether
human inhibitory neurons require MECP2 for proper morpholog-
ical development, we costained the neuronal culture with MAP2
and GAD67 and found a significant soma size reduction in
mutant cells (Figures 2A and 2B). We also investigated whether
MECP2 deletion affects neurite arborization of individual Synap-
sin-GFP-labeled neurons. Sholl analysis revealed significantly
reduced neurite complexity in MECP2 mutant neurons (Figures
2E and 2F). Utilizing a dual-chamber multielectrode array culture
system that allows continuous monitoring of the appearance of
spontaneous activities, we plated control and mutant neurons
side by side (Figure 2G) and found that action potential rates
were significantly reduced in mutant neurons (Figures 2H–2J).
We conclude that MECP2 deletion impairs neuronal develop-
ment and function.
MECP2 Mutant Neurons Display Global Reductions in
Transcription
We next compared isogenic mutant and control cells to assess
the effect of MECP2 deletion on global gene expression. Con-
ventional global transcriptional analyses normalizing individual
gene expression to total RNA (MAS5 for Affymetrix) indicated
that the majority of genes were unchanged (Figures 3A and
3B). When the distribution of expression changes of all genes
was examined, a minimal median change in mutant NPs and
2-week-differentiated mutant neurons and a small increase in
4-week-differentiated mutant neurons were found (Figure 3C).
The minor gene expression changes in MECP2 mutant neurons,
especially those found in the male WIBR1-Mut neurons, were
consistent with previous findings in Mecp2 hemizygous mutant
mice (Kriaucionis et al., 2006; Nuber et al., 2005; Tudor et al.,
2002; Urdinguio et al., 2008). We found that the female WIBR3-
Mut neurons displayed a higher level of differential expression
compared to their isogenic controls, with a similar distribution
of upregulated and downregulated genes at 2 weeks and slightly
more upregulated genes at 4 weeks of differentiation (Figure 3B).
The validity of conventional gene expression analyses, which
usually are based on the assumption that total RNA content
per cell remains constant, has recently been questioned. It was
discovered that c-Myc overexpression results in a significant
increase in nuclear size and an amplified per-cell expression of
more than 90% of all genes. However, when the expression
data were normalized using the traditional analysis method,
i.e., normalization to total input RNA, this genome-wide gene
expression change was not detected (Lin et al., 2012; Love´n
et al., 2012). These observations are highly relevant to MECP2
mutant cells, which display a significantly reduced soma and
nuclear size (Figures 2A–2D).
To investigate whether the reduced soma and nuclear size of
MECP2 mutant cells affected per-cell RNA levels, we isolated
total RNA from equal numbers of NPs and differentiating neu-
rons. Figure 3D shows that mutant neurons at 2 and 4 weeks
of differentiation have 27% and 47% less total RNA, respec-
tively, as compared to their isogenic controls. A significant
reduction of differently sized ribosomal RNAs (rRNAs) was found
Figure 2. MECP2 Mutant Human Neurons Show Morphological and Electrophysiological Defects
(A) Representative images of Synapsin-GFP (middle panels) are shown, and immunostaining with antibodies against MAP2 (left panels) shows reduced soma size
in WIBR3-Mut1 neurons. Costaining for MAP2 and GAD67 (right panels) revealed reduced soma size in WIBR3-Mut1 inhibitory neurons. Scale bar, 10 mm.
(B) Quantitative analysis of MAP2+ neuron, Synapsin-GFP+ neurons, andMAP2+GAD67+ inhibitory neurons demonstrated reduced soma size inMECP2mutant
neurons compared to their isogenic controls.
(C) Representative images of Synapsin-GFP+ control and MECP2 mutant neurons. Nuclei are highlighted with DAPI staining. Scale bar, 10 mm.
(D) Quantitative analyses of neuronal nucleus size demonstrated smaller nucleus in MECP2 mutant neurons.
(E) Synapsin-GFP labeling revealed the neurite morphology of control and mutant neurons. Scale bar, 10 mm.
(F) Quantitative analyses of neurite morphology of Synapsin-GFP+ neurons showed that MECP2 mutant neurons had reduced number of neurite intersections
compared to controls.
(G andH)Multielectrode array analyses of isogenic control andMECP2mutant neurons. Control andmutant neurons were plated on the sameMED-64 arrays (G).
Spike rasters depict spontaneous activities during a 5 min recording (H). Note the gradual increase of activity in control neurons (electrode 33–64) and the near
absence of activity in mutant neurons (electrode 1–32).
(I and J) Reduced spike rate in both WIBR1-Mut and WIBR3-Mut neurons.
Results are mean ± SEM. *p < 0.05, **p < 0.01.
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transfer RNA (tRNA) constituting the majority of total RNA (Fig-
ure 3E). In contrast, NPs of either genotype had similar levels
of total RNA and rRNA (Figures 3D and 3E).
To assess how normalization to input cell number affects the
interpretation of global transcriptional analyses, we prepared
RNA from an identical number of control and mutant cells and
added synthetic RNA spike-in standards as surrogates for cell
numbers (Love´n et al., 2012). After normalizing gene expression
to RNA spike-ins, an average of 50% of all genes were downre-Cegulated more than 1.2-fold in mutant neurons at 2 weeks of dif-
ferentiation (Figures 3F and 3G; 62.3% in WIBR1-Mut; 37.9% in
WIBR3-Mut). At 4 weeks of differentiation, the percentage of
downregulated genes in MECP2 mutant neurons was 60% (Fig-
ures 3F and 3G; 54.1% in WIBR1-Mut; 64.6% in WIBR3-Mut). In
contrast, only about 7%of all genes were upregulated more than
1.2-fold at 2 and 4 weeks of differentiation (2.4% and 5.8% in
WIBR1-Mut; 12.6% and 7.4% in WBIR3-Mut). At the NP stage,
expression levels were more evenly distributed, with 14%
downregulated and 8% upregulated 1.2-fold or more (13.5%ll Stem Cell 13, 446–458, October 3, 2013 ª2013 Elsevier Inc. 449
Figure 3. Reduced Total RNA and Global Transcriptional Downregulation in MECP2 Mutant Neurons
(A and B) Heatmaps showing the fold change of expression in mutant versus control WIBR1 (A) or WIBR3 (B) cells using a standard Affymetrix microarray
normalization method (MAS5).
(C) Boxplots of transcriptional changes between control and mutant cells, normalized by standard Affymetrix microarray normalization method (MAS5).
(D) Two- and four-week-differentiated MECP2mutant neurons have reduced total RNA levels compared to their isogenic controls. Note the comparable levels of
total RNA in control and mutant NPs.
(E) TBE urea gel of ethidium-bromide-stained total RNA extracted from equivalent numbers of control and MECP2mutant cells. Bands correspond to 5.8S rRNA,
5S rRNA, and tRNA.
(F and G) Heatmap showing the fold change of expression in mutant versus control WIBR1 (F) or WIBR3 (G) cells using RNA spike-in standards.
(H) Boxplots of transcriptional changes between mutant and control cells, normalized by RNA spike-in standards.
(I) Gene ontology analysis of genes commonly downregulated in 4-week-old mutant neurons. Graph shows the top GO terms of biological processes significantly
affected in MECP2 mutant neurons.
(J and K) Boxplots of fold transcriptional changes of all genes, subdivided into four equal groups based on their expression levels in 4-week-differentiatedWIBR1-
Con (J) and WIBR3-Con (K) neurons.
(L and M) Boxplots of gene expression distributions in 4-week-differentiated control neurons (L) or control NPs (M), based on whether they were upregulated or
downregulated in the isogenic mutant neurons.
Results are mean ± SEM. *p < 0.05, **p < 0.01. See also Figure S2.
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upregulated and 10.5% downregulated in WIBR3-Mut).
A similar global downregulation was seen when a higher
threshold (1.5-fold) was used, which shows that mutant neurons
on average had 10 times the number of downregulated genes
compared to upregulated ones. By examining the distribution of
expression changes of all genes, we saw a median 25% percent
reduction in 2-week-differentiated mutant neurons and 37%
reduction in 4-week-differentiated mutant neurons (Figure 3H,450 Cell Stem Cell 13, 446–458, October 3, 2013 ª2013 Elsevier Inc.32.2% and 29.6% in WIBR1-Mut; 17.1% and 43.7% in WIBR3-
Mut), whereas average gene expression in mutant NPs was not
significantly changed. Gene ontology analysis revealed that
genes involved in the biological processes of transcription and
translation were enriched among the most significantly downre-
gulated genes (Figure 3I). Through this series of analyses, we
found that female mutant WIBR3 cells displayed more differen-
tial gene expression changes than male WIBR1 mutant cells
when compared to the isogenic controls (Figures 3F–3H),
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Global Transcriptional Repression in Rett Syndromepossibly reflecting the inherent stability differences between
cultured male and female pluripotent stem cells (Anguera et al.,
2012; Mekhoubad et al., 2012; Zvetkova et al., 2005). Indeed,
WIBR3-derived female NPs and neurons had increased expres-
sion levels of X-linked genes as compared to WIBR1-derived
male cells (Figures S2A and S2B). Importantly, these unbiased
global gene expression analyses revealed a consistent
genome-wide transcriptional reduction in both WIBR1 and
WIBR3 mutant neurons.
MECP2 Mutant Neurons Display Preferential
Reductions of Active Transcription
To further quantify expression changes, we divided all genes
based on their expression levels (in control neurons) into four
equal groups. Figures 3J and 3K show that higher expression
was correlated with a more dramatic extent of downregulation
in 4-week-oldmutant neurons. Themost highly expressed genes
(top 25%) showed a median 70% reduction in expression,
whereas the lowest expressed genes (bottom 25%) showed
only a median 4% reduction. A similar trend was seen in
2-week-old neurons (Figures S2C and S2D), but not in NPs (Fig-
ures S2E and S2F). In addition to analyzing the expression of all
genes, we examined genes that were significantly upregulated or
downregulated in 4-week-old mutant neurons of both WIBR1
and WIBR3 genetic background (85 and 7,265 commonly upre-
gulated and downregulated genes). Figure 3L and Figure S2G
show that genes that were downregulated in the absence of
MECP2 were expressed at a substantially higher level as
compared to genes that were upregulated. Notably, when the
expression levels of genes that were significantly upregulated
or downregulated in mutant NPs were examined, no such corre-
lation was seen (Figure 3M). The selective group of upregulated
genes in 4-week-oldmutant neurons, albeit numerically few, was
less active in wild-type neurons and may represent instances
where MECP2 binding exerted repressive effects. Indeed,
some of the upregulated genes (CALCR, Nanog, UGT2B10)
were predominantly expressed outside of the nervous system,
and may be misexpressed due to the lack of MECP2-mediated
repression (Figures S2H–S2J). Our results demonstrate that
active genes were more susceptible to downregulation upon
MECP2 deletion, strongly indicating a transcriptional activator
function for MECP2.
We compared the specificity of transcriptional reduction of
genes involved in nervous system development (Figure S3A,
http://human.brain-map.org) and in synapse formation (Pirooz-
nia et al., 2012). Figures 4A shows that both groups of genes
were collectively downregulated in MECP2 mutant neurons. In
contrast, the expression levels of a group of genes known to
be specifically expressed in astrocytes and oligodendrocytes
were largely unaffected in mutant cells (Figure 4A) (Cahoy
et al., 2008).
Recent reports have suggested a role for MECP2 in regulating
the expression of immediate early genes, a distinct group of
genes found to be critically dependent on transcriptional regula-
tion (Kron et al., 2012; Su et al., 2012; Tullai et al., 2007; Yasui
et al., 2007). When comparing the expression of a group of
immediate early genes known to be activated by neuronal activity
(Bateup et al., 2013), these genes were expressed at relatively
high levels in control neurons (Figure S3B) and collectively down-Ceregulated in mutant neurons (Figure 4B). Quantitative RT-PCR
further confirmed the downregulation of some of these key
immediate early genes, such asArc, Fos,NPAS4, andBDNF (Fig-
ure 4C). This coincides with mutant neurons displaying reduced
network activities (Figures 2G and 2H) and thereby correlates
transcription reduction with physiological impairment. To further
investigate whether MECP2 plays a direct role in regulating
immediate early gene expression, we treated control andmutant
neurons with tetrodotoxin which was followed by depolarization
with KCl. Quantitative RT-PCR revealed significant increases in
Arc, Fos, NPAS4, and BDNF expression in control neurons, while
mutant neurons failed to display such induction (Figure 4D).
A recent study in mice showed that Mecp2 binds to both
5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC),
with the latter enriched within active genes (Melle´n et al.,
2012). This observation is consistent with our finding that binding
of MECP2 facilitates active transcription and predicts that genes
with higher 5hmC/5mC ratios would be more likely to be down-
regulated in the absence of MECP2. We extracted the ranking of
5hmC/5mC ratios from wild-type mouse neurons and correlated
the expression of these genes in 4-week-old human neurons.
Figures 4E and 4F show that genes with higher 5hmC/5mC ratios
were more highly expressed in control human neurons (top
panels) and were more likely downregulated in MECP2 human
mutant neurons (lower panels). In contrast, gene expression
changes seen in MECP2 mutant NPs were not correlated
to the 5hmC/5mC ratio (Figures 4G and 4H), suggesting that
this mode of MECP2-mediated differential gene expression is
specific for differentiated neurons. Our findings suggest that
MECP2 exerts bimodal regulation of gene expression that is
dictated by its binding to 5hmC or 5mC.
MECP2 Mutant Neurons Display Impaired Global
Translation and AKT/mTOR Activity
A prominent group of genes affected in MECP2 mutant neurons
were ribosomal proteins (Figure 5A), which were collectively
downregulated at 4 weeks of differentiation (Figures S4A and
S4B). Combined with the reduced level of rRNAs (Figure 3D),
these findings predicted impaired capacity for translation. To
evaluate nascent protein synthesis, we measured 35S-Cys/Met
incorporation during a 30min period. Figure 5B shows that, while
mutant NPs had similar levels of incorporation as their isogenic
controls, 3-week-differentiatedmutant neurons displayed signif-
icantly reduced incorporation (Figure 5C), suggesting impaired
protein synthesis.
We have previously reported that Mecp2 mutant mice could
be partially rescued either by overexpression of BDNF or by sys-
temic delivery of IGF1 (Chang et al., 2006; Tropea et al., 2009),
consistent with a reduced BDNF mRNA and protein level in
brains of Mecp2 mutant mice (Chang et al., 2006). Indeed,
MECP2 mutant neurons had both lower basal and KCl-induced
levels of BDNFmRNA (Figures 4C and 4D). Also, MECP2 mutant
neurons secreted reduced levels of BDNF protein as measured
by ELISA (Figure 5D). TrkB and IGF1R, the high affinity receptors
for BDNF and IGF1, were abundant in human neurons and were
expressed at similar levels in control and mutant neurons as
evaluated by quantitative RT-PCR (Figure S4C). We further
examined the activities of key intracellular signaling pathways
downstream of these receptors, focusing on the AKT/mTORll Stem Cell 13, 446–458, October 3, 2013 ª2013 Elsevier Inc. 451
Figure 4. Preferential Reduction of Active Transcription in MECP2 Mutant Neurons
(A and B) Boxplots of transcriptional changes between mutant and control cells, in groups of genes identified as glia-specific (A, left), synaptic (A, right), and
immediate-early (B).
(C) Quantitative RT-PCR analysis confirmed the basal downregulation of immediate-early genes (Arc, Fos, NPAS4, and BDNF) in WIBR1-Mut and WIBR3-Mut
neurons.
(D) Quantitative RT-PCR analysis revealed the lack of activity-induced upregulation of immediate-early genes (Arc, Fos, NPAS4, and BDNF) in WIBR1-Mut and
WIBR3-Mut neurons.
(E–H) Correlation of wild-type gene expression levels (top panels) and gene expression changes in the absence of MECP2 (lower panels) to the 5hmC/5mC ratios
from mouse brain. Note that higher 5hmC/5mC ratio correlated with higher expression levels and increased probability of downregulation in 4-week-old mutant
neurons, but not in mutant NPs.
Results are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S3.
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translation (Zoncu et al., 2011). Mutant neurons displayed
severely diminished levels of phospho-AKT and phospho-S6
as seen by immunostaining (Figures 5E–5H).
We next investigated whether treatment with BDNF or IGF1
could activate the AKT and S6 pathway and affect the in vitro
mutant phenotype. Three-week treatment with BDNF or IGF1
significantly rescued the soma size and dendritic complexity
deficits seen in MECP2 mutant neurons (Figures 5I and 5J).
Although BDNF and IGF1 treatment did not significantly affect
the total RNA content per cell (not shown), nascent protein syn-
thesis as evaluated by 35S-Cys/Met incorporation levels was
elevated in treated mutant neurons (Figure 5K). Furthermore,
BDNF and IGF1 treatment significantly increased the percentage
of MAP2+ mutant neurons that costained for phospho-AKT and
phospho-S6 (Figures 5L and 5M). Thus, these results strongly
support the notion that reduced levels of new protein synthesis452 Cell Stem Cell 13, 446–458, October 3, 2013 ª2013 Elsevier Inc.in MECP2 mutant neurons were accompanied with impaired
activities of the AKT/mTOR pathways and that treatment with
exogenous growth factors promoted protein synthesis via
enhancing AKT/mTOR signaling activities.
To further investigate the effects of promoting protein synthe-
sis on the mutant phenotypes, we used a genetic approach to
activate the AKT/mTOR pathway. PTEN is a known negative
regulator of PI3K, an upstream component of the AKT/mTOR
pathway (Sansal and Sellers, 2004). Ablation of PTEN has been
shown to lead to constitutive activation of the AKT/mTOR
pathway in a variety of tissues, including the brain (Kwon et al.,
2006). We transduced control and mutant NPs with lentiviruses
encoding a PTEN shRNA that has been proven to knock down
PTEN efficiently (Luikart et al., 2011). Immunoblotting confirmed
significant reductions in PTEN protein and corresponding
increases in the levels of phospho-AKT and phospho-S6
proteins upon transduction (Figures 6A–6C). This lentivirus
Figure 5. Reduced Protein Synthesis and AKT/mTOR Activity in MECP2 Mutant Neurons Were Rescued by BDNF and IGF1 Treatment
(A) Boxplots of transcriptional changes of ribosomal proteins between mutant and control cells.
(B and C) MECP2 mutant neurons (B), but not NPs (C), have reduced protein synthesis, as measured by 35S-Cys/Met incorporation.
(D) MECP2 mutant neurons have reduced levels of secreted BDNF protein, as measured by BDNF ELISA.
(E–H) MAP2+ MECP2 mutant neurons have reduced levels of phospho-AKT (E and G) and phospho-S6 (F and H) compared to their isogenic controls.
Scale bar, 10 mm.
(I) BDNF or IGF1 treatment partially rescues the soma size defect in MECP2 mutant MAP2+ neurons.
(J) BDNF or IGF1 treatment increases neurite complexity in MECP2 mutant Synapsin-GFP+ neurons.
(K) BDNF or IGF1 treatment enhances protein synthesis in MECP2 mutant neurons as measured by 35S-Cys/Met incorporation.
(L and M) Quantitative analyses of MAP2+ neurons costained with antibodies against phospho-AKT or phospho-S6 demonstrate that BDNF or IGF1 treatment
partially ameliorated the AKT and S6 signaling defects in MECP2 mutant neurons.
Results are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005. See also Figure S4.
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Figure 6. PTEN Knockdown Rescues Protein Synthesis and Morphological Defects in MECP2 Mutant Neurons
(A–C) Immunoblot analysis for PTEN (A and B) and phospho-AKT and phospho-S6 (A and C) demonstrate effective knockdown of PTEN and activation of AKT/S6
pathway using PTEN shRNA.
(D) Representative images of Synapsin-GFP+ MECP2 mutant neurons treated with vector (left) or PTEN shRNA-mCherry (right). Scale bar, 10 mm.
(E and F) PTEN-shRNA increased soma size (E) and neurite complexity (F) in MECP2 mutant neurons.
(G) PTEN-shRNA enhanced protein synthesis in MECP2 mutant neurons, as measured by 35S-Cys/Met incorporation. Inhibition of mTOR signaling by rapamycin
suppressed PTEN-knockdown-induced increase in protein synthesis.
Results are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.005.
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fication of individual PTEN knockdown cells. Figures 6D–6F
show that PTEN knockdown significantly increased soma size
and neurite arborization as compared to vector-treated cells.
This was accompanied by an increase in nascent protein synthe-
sis as measured by 35S-Cys/Met incorporation (Figure 6G).
These results demonstrate that genetic activation of the AKT/
mTOR pathway in mutant neurons promoted protein synthesis
and was sufficient to ameliorate the disease-related cellular
impairments.
MECP2Mutant Neurons Display Impaired Mitochondrial
Function
The expression of all genes predicted to encode mitochondrial
proteins (Pagliarini et al., 2008) was significantly downregulated
in mutant neurons (Figure 7A). This is consistent with mito-
chondrial protein genes as a group being highly expressed
(Figure S5A). A survey of all genes encoding mitochondrial ribo-
somal proteins revealed that similar to cytoplasmic ribosomal
protein genes (Figure S4), the majority of these genes were
also downregulated (Figures S5B and S5C). Consistent with454 Cell Stem Cell 13, 446–458, October 3, 2013 ª2013 Elsevier Inc.this observation, expression of the UQCRC1 gene, which was
previously suggested to be upregulated in Mecp2 mutant
mice (Kriaucionis et al., 2006), was in fact downregulated in
MECP2 mutant neurons (Figure S5D). To investigate the phys-
iological consequences of these transcriptional changes, we
measured cellular oxygen consumption. Despite having normal
mitochondrial mass per cell as measured by mitochondria-
selective dye uptake, mutant neurons displayed a 40% reduc-
tion in their basal oxygen consumption and a similar reduction
in the maximal respiration rate observed upon FCCP addition
(Figures 7B and 7C). These results strongly suggest that
the capacity of the mitochondrial electron transport chain is
reduced in mutant neurons. Given that mitochondrial mass
was similar between control and mutant neurons, this capacity
could be limited by the availability of substrate due to an overall
decrease in glucose metabolism. To explore this possibility
further, we measured rates of glucose consumption and lactate
production in these cells (Figures 7D and 7E). No differences
in glucose consumption or lactate production were observed
in these cells. These data are consistent with the decrease in
respiration being explained by downregulation of mitochondrial
Figure 7. MECP2 Mutant Human Neurons Show Impaired Mitochondrial Function
(A) Boxplots of transcriptional changes of mitochondrial protein genes between mutant and control cells.
(B) Quantification analyses of mitochondrial mass as measured by mito-tracker fluorescence, normalized to Hoechst intensity.
(C) Measurement of oxygen consumption reveals reduced respiration at the basal and FCCP uncoupled states in MECP2 mutant neurons.
(D and E) Quantification of the basal consumption of glucose and production of lactate in control and MECP2 mutant neurons.
(F and G) Amodel of MECP2-regulated gene expression in human neurons. MECP2 is present on both inactive genes (marked by 5mC) and active genes (marked
by 5hmC). In RTT neurons, deletion of MECP2 induces upregulation of a small group of lowly expressed genes, indicating a repressor function for MECP2 for
these genes. The main effect of MECP2 deletion, however, is a genome-wide downregulation of a majority of genes, with preferential effects on those that are
highly expressed. This demonstrates a global activator role for MECP2 (G). This global transcriptional repression in RTT neurons leads to reduced protein
synthesis, AKT/mTOR activity, soma and nucleus size, neurite complexity, electrophysiological activity, and mitochondrial function.
Results are mean ± SEM. ***p < 0.005. See also Figure S5.
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DISCUSSION
Our study shows that compared to their isogenic controls, hu-
man neurons that lack MECP2 have smaller nuclei and soma,
as well as less complex dendritic arborization. This decrease in
cell size was coupled with a previously unappreciated reduction
in total RNA on a per-cell level. In agreement with a recent report
of decreased RNA synthesis in Mecp2 mutant mouse neurons
(Yazdani et al., 2012), our findings demonstrate that MECP2
mutant human neurons, but not NPs, have reduced total RNA
and rRNA. More importantly, unbiased global transcription ana-
lyses revealed a striking genome-wide downregulation in mutant
human neurons. These findings highlight a drastic decline in the
integrity of the neuronal transcriptional program in the absence
of MECP2. Furthermore, although the downward shift in geneCeexpression is widespread, the transcriptional activity of genes
directly correlated with their probability to be downregulated
upon MECP2 deletion. In addition, genes known to have higher
ratios of 5hmC compared to 5mC were more likely downregu-
lated in an MECP2-dependent manner in neurons, but not in
NPs. This preferential downregulation of active genes strongly
supports a crucial role for MECP2 in facilitating active transcrip-
tion in human neurons.
One of the key conclusions from our work is that MECP2 can
act as a global activator of gene expression in neurons, a conclu-
sion that contrasts with the widely accepted notion of MECP2
acting as a transcriptional repressor (Ebert et al., 2013; Lyst
et al., 2013). Our results are based on gene expression analyses
using the addition of synthetic RNA spike-in standards, which
allowed unbiased gene expression analysis in equal numbers
of cells. In contrast, traditional gene expression measurements
are based on the assumption that control and experimental cells
have a similar amount of total RNA and thus are normalized toll Stem Cell 13, 446–458, October 3, 2013 ª2013 Elsevier Inc. 455
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in RTT neurons, the amount of total RNA differs between exper-
imental and control cells. The present and previous results (Lin
et al., 2012; Love´n et al., 2012) emphasize the necessity of a
‘‘per-cell’’ perspective for interpreting genome-wide gene
expression data, particularly when the experimental manipula-
tion could result in perturbations of global transcription.
It was surprising that control andmutant cells derived from the
female WIBR3 ESCs displayed higher levels of gene expression
changes than the male WIBR1-derived cells. While we have no
mechanistic explanation for this finding, global differences in
DNA methylation between male and female mouse ESCs have
been reported previously (Zvetkova et al., 2005), and female
human ESCs and iPSCs also display variable gene expression
(Anguera et al., 2012; Mekhoubad et al., 2012). The lack of
MECP2 mRNA and protein expression in female WIBR3-Mut
cells demonstrates that theMECP2 locus on the inactive X chro-
mosome remained silent and the global transcriptional downre-
gulation and the preferential vulnerability of active genes were
independently identified in mutant male and female cells. Thus,
our findings ascertain an unambiguous role for MECP2 in facili-
tating active transcription on a genome-wide scale.
Furthermore, we demonstrated that mutant neurons display
several disease-related physiological changes as compared
to their isogenic controls. Using multielectrode arrays, we fol-
lowed the course of neuronal maturation and identified a sig-
nificant reduction in spontaneous network electric activity in
mutant neurons. Prompted by the finding that many mitochon-
drial protein genes were downregulated in the absence of
MECP2, we investigated respiration in whole neuronal popula-
tions and identified significantly impaired metabolic function
in mutant neurons. This echoes earlier observations that RTT
shares hallmarks of mitochondrial encephalopathies and was
thought to be a mitochondrial disorder characterized by dysre-
gulation of lactate metabolism (Cornford et al., 1994). These
findings provide novel insights into the manifestation of disease
symptoms for RTT and potential future avenues of therapeutic
intervention.
Exogenous growth factors such as BDNF and IGF1 are effec-
tive in mitigating disease-related symptoms in Mecp2 mutant
mice (Chang et al., 2006; Kline et al., 2010; Tropea et al., 2009)
and in patient iPSC-derived neurons (Marchetto et al., 2010).
The underlying mechanism for these reversals remains to be
identified. Using isogenic human cells we demonstrated that
MECP2 mutant neurons have significantly lower protein synthe-
sis activity. Furthermore, our study identified a severe defect in
the activity of the AKT/mTOR signaling cascade, a crucial
pathway known to directly modulate protein synthesis that is
induced by BDNF and IGF1 (Ricciardi et al., 2011). Genetic acti-
vation of the AKT/mTOR pathway by PTEN ablation ameliorated
the protein synthesis and the neural morphological defects in
MECP2 mutant neurons, offering further evidence that protein
synthesis impairment is central to RTT pathology. Thus, our
results provide mechanistic insights into impairments seen in
MECP2 mutant neurons and suggest the unifying hypothesis
that a defect in the global control of transcription and translation
is a fundamental cause of RTT-related symptoms.
The critical dependence on MECP2 in maintaining gene
expression appears to be a phenomenon unique to differentiated456 Cell Stem Cell 13, 446–458, October 3, 2013 ª2013 Elsevier Inc.neurons and not seen in NPs. The critical role of MECP2 in neu-
rons is supported by previous studies in mice showing that abla-
tion of Mecp2 specifically in postmitotic neurons was sufficient
to produce RTT symptoms (Chao et al., 2010; Chen et al.,
2001). Thus, the mechanism by which re-expression of Mecp2
reverses RTT phenotypes may reside in its ability to reinstate
proper gene expression regulation, thus reversing the down-
stream transcriptional and translational impairments. Consistent
with the notion that the RTT phenotype is reversible, BDNF, IGF1
addition, and PTEN knockdown rescued the disease-related
phenotype in mutant neurons, suggesting that boosting protein
synthesis by activation of the AKT/mTOR pathway may repre-
sent a potential therapeutic strategy for RTT.
EXPERIMENTAL PROCEDURES
TALEN Construct and Genome Editing in Human ESCs
TALENs-mediated gene targeting was performed as previously described
(Hockemeyer et al., 2011). The DNA binding sites of the TALENs used for
targeting exon 3 of MECP2 are 50-GCAGCCATCAGCCCACCACT-30 and
50-CTCTGCTTTGCCTGCCT-30.
Cell Culture and Neural Differentiation
HESC linesWIBR1 andWIBR3were cultured as previously described (Lengner
et al., 2010). To induce neural differentiation, increasing amounts of N2 media
(25%, 50%, 75%, and 100%) were added to mTeSR medium every other day
while maintaining 2.5 mM dorsomorphin. NPs were passaged at day 20–24 us-
ing accutase and cultured in N2 media with 20 ng/ml bFGF. NPs were further
differentiated in differentiation medium without bFGF. For morphological and
electrophysiological analyses, cells were lifted using accutase and replated
onto coverglass or culture dish.
RNA Preparation, Microarray Analysis, and Quantitative RT-PCR
Total RNA extraction and RNA electrophoresis was performed as previously
described (Lin et al., 2012). RNA spike-in controls were added to total RNA
extracted from equal numbers of cells, as previously described and following
the manufacturer’s recommendations (Love´n et al., 2012). RNA was reverse
transcribed using Superscript III reverse transcriptase (Invitrogen) with random
hexamer primers. Transcript abundance was determined by quantitative
PCR using SYBR Green PCR mix (Applied Biosystems). Raw Ct values were
normalized to GAPDH or ERCC spike-in standards.
Protein Assays
Total protein extraction and immunoblotting was performed as previously
described (Li et al., 2008). Metabolic labeling of newly synthesized protein
(Thoreen et al., 2012) was performed by labeling with 165uCi of EasyTag
EXPRESS 35S protein labeling mix (Life Technologies) for 30 min. The concen-
tration of secreted BDNF protein in culture medium was measured using a
BDNF ELISA Kit (Promega) (Li et al., 2012).
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